Generic Name and Formulations:
Polyethylene glycol 3350 420g, sodium bicarbonate 5.72g, sodium chloride 11.2g, potassium chloride 1.4g; per 4L of soln; pwd for reconstitution; cherry, lemon-lime, orange, or pineapple flavor.
Braintree Laboratories, Inc.
Indications for NuLYTELY:
Bowel cleansing before colonoscopy.
May consume water or clear liquids during and after completion of bowel prep up until 2hrs before procedure. Drink 240mL orally every 10 mins or 20–30mL/min by NG tube until rectal effluent is clear or 4L consumed. May interrupt if severe GI disturbances occur.
<6 months: not recommended. ≥6 months: May consume water or clear liquids during and after completion of bowel prep up until 2hrs before procedure. Drink 25mL/kg per hour orally or by NG tube until rectal effluent is clear or 4L consumed. May interrupt if severe GI disturbances occur.
GI obstruction. Bowel perforation. Gastric retention. Ileus. Toxic colitis or megacolon.
Not for direct ingestion. Correct fluid/electrolyte abnormalities before use. History of prolonged QT, uncontrolled arrhythmias, recent MI, unstable angina, CHF, or cardiomyopathy: increased risk of arrhythmias; consider ECGs at pre-dose and post-colonoscopy. History or risk of seizures. Renal impairment; monitor baseline and post-colonoscopy electrolytes, creatinine, BUN. Inflammatory bowel disease. Rule out suspected GI obstruction/perforation before administering. Severe ulcerative colitis. Impaired gag reflex. Semi- or unconscious patients. Risk of regurgitation or aspiration. Monitor young children (<2yrs) for hypoglycemia. Maintain adequate hydration. Pregnancy (Cat.C). Nursing mothers.
Caution with drugs that increase risk of fluid/electrolyte abnormalities, arrhythmias or QT prolongation. Drugs that may lower the seizure threshold (eg, tricyclic antidepressants), alcohol or benzodiazepine withdrawal, known or suspected hyponatremia: may increase risk of seizures. Concomitant diuretics, ACE inhibitors, ARBs, NSAIDs; may affect renal function. Avoid concomitant stimulant laxatives (eg, bisacodyl, sodium picosulfate). Oral drugs administered within 1hr of start of Nulytely may not be absorbed.
Nausea, abdominal fullness and bloating, cramps, vomiting, anal irritation; seizures, arrhythmias, mucosal ulcerations and ischemic colitis. Children: also dehydration or hypokalemia.
Disposable jug (4L)—1
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|